Literature DB >> 27913481

Anti-Xa monitoring of low-molecular-weight heparin in adult patients with cancer.

Lisa Baumann Kreuziger1, Michael Streiff2.   

Abstract

A 68-year-old man developed a right femoral vein deep vein thrombosis and bilateral pulmonary embolism while receiving chemotherapy for stage IV prostate cancer. His creatinine at diagnosis is 1.4 mg/dL, with an estimated clearance of 63 mL/min. In patients with cancer, should low-molecular-weight heparin treatment be dosed according to weight, or adjusted using anti-Xa levels?
© 2016 by The American Society of Hematology. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27913481      PMCID： PMC6142453          DOI： 10.1182/asheducation-2016.1.206

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN： 1520-4383


  14 in total

1.  Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin.

Authors:  L T Busby; A Weyman; G M Rodgers
Journal:  Am J Hematol       Date:  2001-05       Impact factor: 10.047

2.  Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

4.  Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.

Authors:  Wendy Lim; Francesco Dentali; John W Eikelboom; Mark A Crowther
Journal:  Ann Intern Med       Date:  2006-05-02       Impact factor: 25.391

5.  Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism.

Authors:  Nils Kucher; Rene Quiroz; Sylvia McKean; Arthur A Sasahara; Samuel Z Goldhaber
Journal:  Vasc Med       Date:  2005-11       Impact factor: 3.239

6.  Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.

Authors:  Agnes Y Y Lee; Pieter W Kamphuisen; Guy Meyer; Rupert Bauersachs; Mette S Janas; Mikala F Jarner; Alok A Khorana
Journal:  JAMA       Date:  2015-08-18       Impact factor: 56.272

7.  Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group.

Authors:  M Alhenc-Gelas; C Jestin-Le Guernic; J F Vitoux; A Kher; M Aiach; J N Fiessinger
Journal:  Thromb Haemost       Date:  1994-06       Impact factor: 5.249

8.  Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

Authors:  Paolo Prandoni; Anthonie W A Lensing; Andrea Piccioli; Enrico Bernardi; Paolo Simioni; Bruno Girolami; Antonio Marchiori; Paola Sabbion; Martin H Prins; Franco Noventa; Antonio Girolami
Journal:  Blood       Date:  2002-07-12       Impact factor: 22.113

9.  Management of refractory venous thrombosis associated with malignancy using a supra-therapeutic enoxaparin regimen.

Authors:  M S Cunningham; R Gilmore; D O'Donnell; J S O'Donnell
Journal:  Ir J Med Sci       Date:  2008-08-27       Impact factor: 1.568

10.  Clinical Use of Anti-Xa Monitoring in Malignancy-Associated Thrombosis.

Authors:  Sarah Yentz; Oluwatoyosi A Onwuemene; Brady L Stein; Elizabeth H Cull; Brandon McMahon
Journal:  Thrombosis       Date:  2015-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.